Home › All Companies › APVO › Annual Report

Aptevo Therapeutics Inc. (APVO) — Annual Report

AI-Powered SEC Filing Analysis

← All APVO filings
Latest Annual Report Filed: 2026-03-26

Key Insights

  • Aptevo Therapeutics has a significant number of leases, with various lease terms extending through 2030, indicating the company's operational footprint and space requirements.
  • The company has issued various warrants and restricted stock units as part of its equity compensation plans, potentially diluting existing shareholders over time.
  • Aptevo Therapeutics has raised additional capital through registered direct offerings and at-the-market offerings, which could provide funding for ongoing operations and development.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Aptevo Therapeutics Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.